NPNT

Across TCGA pan-cancer cohorts, NPNT Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NPNT data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NPNT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPNT expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

LIHC, LUAD, and KIRC are the cancer types where NPNT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUAD	OS	Median	All	0.234	0.700	<.001	12	view →
KIRC	DFS	Median	All	0.266	0.796	.020	6	view →
STAD	OS	Median	III,IV	0.180	0.530	.012	6	view →
SKCM	OS	Median	III,IV	0.230	0.729	<.001	3	view →
SCLC	DFS	Median	All	1.000	0.399	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NPNT–LIHC (DFS)

Open the LIHC breakdown →